Dimercaprol
Bal (dimercaprol) is a small molecule pharmaceutical. Dimercaprol was first approved as Bal on 1982-01-01. It is used to treat arsenic poisoning, lead poisoning, and nervous system mercury poisoning in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| chemically-induced disorders | D064419 |
Trade Name
FDA
EMA
Bal
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dimercaprol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BAL | Provepharm | N-005939 RX | 1982-01-01 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| OTC monograph not final | 2012-09-04 | |
| 100% pure sweet mint lip balm | OTC monograph not final | 2017-05-01 |
| 2-oak mix, red/white pollen 3-oak mix, black/blackjack/post pollen 3-ragweed mix, giant/short/western pollen 4-pine mix, austrian/loblolly/scotch/w... | Biologic Licensing Application | 2011-03-11 |
| 360 by qur lemon verbena lip balm | C200263 | 2023-10-26 |
| 360 by qur spanish lime lip balm | C200263 | 2023-10-26 |
| 360 by qur vanilla lace lip balm | C200263 | 2023-10-26 |
| 360 by qur watercress mint lip balm | C200263 | 2023-10-26 |
| 365 medicated lip balm | C200263 | 2023-11-03 |
| 365 spiced balsam hand sanitizer wipes | C200263 | 2024-08-15 |
| 3ce pore silky balm | OTC monograph not final | 2016-09-21 |
Show 968 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| lead poisoning | — | D007855 | T56.0 |
| arsenic poisoning | — | D020261 | T57.0 |
| nervous system mercury poisoning | EFO_1001810 | D020262 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0470 | Injection, dimercaprol, per 100 mg |
Clinical
Clinical Trials
343 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pneumonia | D011014 | EFO_0003106 | — | 2 | 4 | 3 | 2 | 68 | 77 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | 1 | 2 | 2 | 1 | 25 | 30 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | 2 | — | — | 1 | 20 | 23 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | 1 | 2 | 1 | 1 | 19 | 23 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | 1 | 3 | 1 | 18 | 22 |
| Covid-19 | D000086382 | — | — | — | — | — | 1 | 19 | 20 |
| Healthy volunteers/patients | — | — | — | 8 | — | — | 1 | 6 | 15 |
| Bacterial infections | D001424 | — | A49 | 5 | — | — | 1 | 2 | 8 |
| Bronchiectasis | D001987 | HP_0002110 | J47 | — | — | — | 1 | 5 | 6 |
| Hiv | D006678 | — | — | 1 | — | — | 1 | 1 | 3 |
Show 10 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute lung injury | D055371 | EFO_0004610 | — | 1 | 2 | 1 | — | 20 | 23 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | — | 1 | — | 10 | 11 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | 1 | — | 10 | 11 |
| Lung injury | D055370 | — | S27.30 | — | 2 | 1 | — | 7 | 9 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 1 | 1 | — | 5 | 6 |
| Neoplasms | D009369 | — | C80 | — | — | 2 | — | 4 | 6 |
| Healthcare-associated pneumonia | D000077299 | — | — | — | — | 1 | — | 4 | 5 |
| Leukemia | D007938 | — | C95 | — | — | 1 | — | 3 | 4 |
| Bronchiolitis | D001988 | HP_0011950 | — | — | — | 1 | — | 2 | 3 |
| Lymphoma | D008223 | — | C85.9 | — | — | 1 | — | 2 | 3 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 4 | 3 | — | — | 19 | 26 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | — | — | 12 | 13 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | 10 | 11 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 3 | — | — | 5 | 8 |
| Pulmonary fibrosis | D011658 | — | — | — | 1 | — | — | 7 | 8 |
| Sepsis | D018805 | HP_0100806 | A41.9 | 3 | 3 | — | — | 4 | 7 |
| Critical illness | D016638 | — | — | — | 1 | — | — | 3 | 4 |
| Idiopathic pulmonary fibrosis | D054990 | — | J84.112 | — | 1 | — | — | 3 | 4 |
| Septic shock | D012772 | — | A48.3 | 3 | 3 | — | — | 1 | 4 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | 1 | 1 | — | — | — | 2 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 1 | — | — | — | 27 | 28 |
| Communicable diseases | D003141 | — | — | 1 | — | — | — | 21 | 22 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | — | — | — | 16 | 18 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 3 | — | — | — | 14 | 17 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 2 | — | — | — | 8 | 10 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | 1 | — | — | — | 3 | 4 |
| Autoimmune diseases | D001327 | HP_0002960 | M30-M36 | 1 | — | — | — | 3 | 4 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | 1 | — | — | — | 3 | 4 |
| Virus diseases | D014777 | — | B34 | 1 | — | — | — | 3 | 4 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | 2 | 3 |
Show 14 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory tract infections | D012141 | — | J06.9 | — | — | — | — | 19 | 19 |
| Aspergillosis | D001228 | EFO_0007157 | B44 | — | — | — | — | 15 | 15 |
| Invasive pulmonary aspergillosis | D055744 | — | B44.0 | — | — | — | — | 11 | 11 |
| Syndrome | D013577 | — | — | — | — | — | — | 10 | 10 |
| Bronchoalveolar lavage | D018893 | BTO_0000155 | — | — | — | — | — | 9 | 9 |
| Interstitial lung diseases | D017563 | HP_0006530 | J84.89 | — | — | — | — | 8 | 8 |
| Pulmonary aspergillosis | D055732 | EFO_1001834 | — | — | — | — | — | 8 | 8 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | — | — | 8 | 8 |
| Lung transplantation | D016040 | — | — | — | — | — | — | 5 | 5 |
| Sclerosis | D012598 | — | — | — | — | — | — | 5 | 5 |
Show 138 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dimercaprol |
| INN | dimercaprol |
| Description | Dimercaprol is a dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury. It has a role as a chelator. It is a dithiol and a primary alcohol. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | OCC(S)CS |
Identifiers
| PDB | — |
| CAS-ID | 59-52-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1597 |
| ChEBI ID | 64198 |
| PubChem CID | 3080 |
| DrugBank | DB06782 |
| UNII ID | 0CPP32S55X (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 67,257 documents
View more details
Safety
Black-box Warning
Black-box warning for: 2-oak mix, red/white pollen 3-oak mix, black/blackjack/post pollen 3-ragweed mix, giant/short/western pollen 4-pine mix, austrian/loblolly/scotch/w..., Acacia american beech american elm arizona ash arizona cypress arroyo willow aspen bald cypress balsam poplar bayberry beefwood/australian pine bir..., Acacia pollen american beech american elm american sycamore arizona ash arizona cypress ash mixture aspen pollen australian pine austrian pine bald..., Balcoltra, Pollens - trees, sycamore, american (eastern) platanus occidentallis animal allergens, ap cattle hair and dander animal allergens, ap dog hair and ..., Urban decay naked skin beauty balm spf 20, Urban decay naked skin dark beauty balm spf20, Urban decay naked skin illuminating beauty balm spf20, Urban decay naked skin light beauty balm spf20
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
183,876 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use